F. Drake

发表

A Novel Human Bone Marrow Stroma-Derived Cell Line TF274 Is Highly Osteogenic In Vitro and In Vivo

U. Prabhakar, D. Lipshutz, I. James, 1998, Calcified Tissue International.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

B. Sugarman, S. Dychter, D. Muchmore, 2015, The AAPS Journal.

The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases*

P. Delmas, J. Delaissé, P. Garnero, 1998, The Journal of Biological Chemistry.

Genomic organization and chromosome localization of the human cathepsin K gene (CTSK).

C. Debouck, S. Van Horn, M. Gowen, 1997, Genomics.

Human Osteoclast Cathepsin K Is Processed Intracellularly Prior to Attachment and Bone Resorption

D. Veber, M. Lark, I. James, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2.

G. Gorbsky, F. Drake, S. Taagepera, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

K. Erhard, R. Keenan, M. Lark, 1999, Bioorganic & medicinal chemistry letters.

Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.

T. Chung, G. Hofmann, M. Mattern, 1990, Cancer research.

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

I. Kola, C. Debouck, P. Hertzog, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Biosynthesis and processing of cathepsin K in cultured human osteoclasts.

I. James, S. Hwang, R. Dodds, 2001, Bone.

Cathepsin K mRNA Detection Is Restricted to Osteoclasts During Fetal Mouse Development

R. Dodds, M. Gowen, J. Connor, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Probably, but More Information Is Forthcoming

B. Votta, M. Gowen, F. Drake, 1998 .

Peptide Aldehyde Inhibitors of Cathepsin K Inhibit Bone Resorption Both In Vitro and In Vivo

D. Veber, A. Badger, I. James, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Expression of cathepsin K messenger RNA in giant cells and their precursors in human osteoarthritic synovial tissues.

R. Dodds, M. Gowen, J. Connor, 1999, Arthritis and rheumatism.

Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation.

B. Amegadzie, K. Ramachandran, J. Connor, 1998, Protein expression and purification.

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

F. Drake, D. Kang, L. Jadin, 2012, Drug Delivery and Translational Research.

Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.

D. Slade, W. G. Harker, F. Drake, 1991, Biochemistry.

Proteolytic Activity of Human Osteoclast Cathepsin K

D. Mcnulty, B. Amegadzie, T. Tomaszek, 1996, The Journal of Biological Chemistry.

In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

R. Hertzberg, G. Hofmann, J. Bartus, 1989, Cancer research.

Cloning and Characterization of a Novel Integrin β3Subunit*

I. James, M. Gowen, J. Connor, 1997, The Journal of Biological Chemistry.

Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy.

R. Hancock, A. Loranger, F. Drake, 1993, Experimental cell research.

Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*)

C. Debouck, I. James, R. Dodds, 1996, The Journal of Biological Chemistry.

Quantitative adaptation of the bacteriophage P4 DNA unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II.

G. Hofmann, C. Mirabelli, F. Drake, 1990, Anti-Cancer Drug Design.

Antitumor Agent Merbarone and Intracellular Inhibition of Topoisomerase II by the In Vitro Updated

R. Hertzberg, G. Hofmann, J. Bartus, 2006 .

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

G. Hofmann, S. Crooke, M. Mattern, 1989, Biochemistry.

Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.

S. Crooke, M. Mattern, C. Mirabelli, 1987, Molecular pharmacology.

Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

D. Sullivan, W. Ross, S. Crooke, 1987, The Journal of biological chemistry.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

B. Sugarman, S. Dychter, D. Muchmore, 2015, The AAPS Journal.

SK&F 110679: comparison of absorption following oral or respiratory administration

D. Wall, Philip L. Smith, F. Drake, 1994 .

Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

M. Mattern, C. Mirabelli, R. Johnson, 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.

T. Chung, S. Crooke, C. Mirabelli, 1989, Proceedings of the National Academy of Sciences of the United States of America.

The new partnership of genomics and chemistry for accelerated drug development.

D. Veber, M. Gowen, F. Drake, 1997, Current opinion in chemical biology.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

K. Erhard, B. R. Smith, M. Lark, 1999, Journal of Pharmacology and Experimental Therapeutics.

Design of potent and selective human cathepsin K inhibitors that span the active site.

J G Gleason, S. Carr, R. DesJarlais, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.

Y. Pommier, D. Kerrigan, R. Ganapathi, 1991, Cancer Communications.

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

F. Drake, D. Kang, L. Jadin, 2012, Drug Delivery and Translational Research.

Cloning and characterization of a novel integrin beta3 subunit.

I. James, S. Hwang, M. Gowen, 1997, The Journal of biological chemistry.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

B. Sugarman, S. Dychter, D. Muchmore, 2015, The AAPS Journal.